Absorption (%I 82+ 9 6 4 t 7* 70t10 52+12 91t 4 91f 3 These results showed : 1) Fat, Ca and hlg absorption were low in 1' 1 fed lfhl but increased with postnatal age. 2) In PI fed I.II\VF, fut absorption was normal, Ca and hlg retention was higher in both studies. Elevated 1,2SDc repeatedly were f o w~d i n premature infants.We investigated i f high 1,25Dc 1) a r e accompanied by a high "free 1,2S0H2D index"(FD1;ratio molar concentrations 1,25011 D/vitominDbinding protein(DBP)) and 2) a r c induced by hypophosp?intemia o r hyperparathyroidism.Matched p a i r s of 14 premature i n f a n t s ( b i r t hweightl430g,980-1700g;ji,range;gestational age33weeks, 31-35wecks) were fed human milk with supplements of p h o s p h o~s ( P ) o r calcium+ P .Vitan~inD lOOOI.U./d were given.P,iPlll(midregional antibody), 2501tD(RIA) , ? , 2 5 k (RPA) ,DBP(radial imunodiffusion) and a l k a l i n e phosphatase(AP) were measured i n serum a t bodyweights 1800+75g(I) and 2150+75g(II) ,respectively.Results were not s i g n i f i c a n t i y -d i fEerent K t h i n p a i r s and therefore a r e indicated together a s x+SD: In an attempt to better understand the control of plasma 1,25-(OH)2~ concentrations cbring puberty, these concentrations have been measured i n 12 g i r l s (age 3 yr 6 mo-8 yr 10 mo) with central precocicus puherty hefore and after 3, 6, 9, 12, 18 end 24 months of treatment with a LHRH analowe (fluserelina, Hoechst). Mean and extreme values for 1,25-(OH)2~ were 76 pg/ml (53-114) before treatment, 68 pg/ml (43-107) and 45 pg/ml (26-87) after 12 and 18-24 months of treatment respectively. N o correlation was found a t any time studied between plasma 1,25-(OH)2~ and : plasma estradiol, plasma DHAS, vaginal maturation index, hone age,hei*t gain (cm/year), p h m a SmC/IGFI, serum calcium, phosphorus and alkaline phosphatase activity. Plasma 1,25(OH)2~ values were also not correlated with plasma basal LH and FSH hefore treatment, but were significantly correlated with plasma basal LH ( r : 0.67, p<0.02) and plasma basal FSH ( r = 0.71, p<0.01) after 12 months of treatment.
Frm these results, m e may speculate that the control of plasma 1,25-(OH)2~ &ring puherty i s not directly dependent upon skeletal grauth, skeletal maturation and ovarian secretion but could be, a t least partially, dependent upon central factors.
AP was normal i n a l l samples. Both 1 ,25Dc and FDI were high when compared t o a d u l t reference values but occurrcd without hypophosphatemia o r hyperparathyroidism. The s i g n i f i c a n c e of high t o t a l and f r e e 1,2SDc i n premature inf a n t s and t h e mechanisms of i t s regulation remain t o be c l u c idated.
2501D&/9
27+1 The syndrome of 1,25(OHI2D r e s i s t a n t r i c k e t s and a l o~e c i a has been shown t o be caused 2 ; defective receotors t o t h e a c t i v e D-metabolite (ESPE, 1982; JCEM 55:1020 JCEM 55: , 1982 . In search of a t h e r a p e u t i c approach, 7 pa l~n t s aged 2-12 years were t r e a t e d .
' .
On a megadose of 60 uq/m /day of l a O H D f o r P months, serum 1,25(OH) 0 increased t o 1100-3000 pg/ml (normal, 20-80 pg/ml), but ricZe2s was not healed.
Treatment of 3 p a t i e n t s with 20 ug/m2/day of 24,25(OH)203.wi t h serum 24,25(OH)2D3 of 6.2-14 nq/ml (normal 1.5-4 ng/ml) f a i l e d t o heal he r i c k e t s . With combined t treatment of 24,25(OH)& ?nd 30 mg/m /day i.v. calcium, r i c k e t s was not healed.
Two c h i l d r e n , 6 and 3 years o l d , received 70 mg/m2/day elementary calcium through an intracaval c a t h e t e r , and serum calcium was maintained a t 9.1-10 mg/dl. Bone pains and muscular weakness disappeared within a week.
Serum PTH and phosphatase normalized a f t e r I and 4 months, r e s p e c t i v e l y .
X-rays dewonstrated complete healing of t h e r a c h i t i c bone changes a f t e r 4 and 6 months, respectively, and t h e c h i l d r e n ' s qrowth a c c e l e r a t e d t o 16.5 and 9.8 cmlyear, respectively. These observations i n d i c a t e t h a t normalization of serum calcium i s s u f f i c i e n t f o r healing of r i c k e t s and growth, even in t h e absence of functioning 1 ,25(0H)2D3 receptors. The therapy reduced incidences of f r a c t u r e s . After 6 mth (FM, TM, G R ) and 1 y r s (FM, G R ) of treatment, BMC was s i g n i f i c a n t l y ( p < 0.01) increased. DBM showed a very slow increment of mineralization with s i g n i f i c a n t recovery only 2.7 y r s a f t e r t h e f i r s t evaluation. No adverse e f f e c t s of 1,25(0H)2D3 therapy were observed; CaU/CrU r a t i o remained in t h e normal range. ed phocytes of t h e s e p a t i e n t s . I n a d d i t i o n , t h e incorporation of '?-thymidine i n t o PHA-stimulated lymphocytes of t h e p a t i e n t s was not reduced by 1,25-(OH) D unlike i n c o n t r o l lymphocytes. These ga4;ent.s were t r e a t e d with la-hydroxyvitamin D [la-OHD ] and calcium(Ca) l a c t a t e . Two p a t i e n t s responded t o 3 u&kg/day3 of la-OHD and 2 g/day of Ca l a c t a t e , and t h e i r blood chemistry and bone i!esions were normalized a f t e r 15 and 36 weeks of treatment. However, t h e most severe case responded only p a r t i a l l y t o 5 ug/kg/day of la-OHD and 2 g/day of Ca l a c t a t e . The alopecia of t h e p a t i e n t s was nat improved by t h e s e treatments. These r e s u l t s suggest t h a t high doses of la-OHD may be u s e f u l i n treatment of MDR I1 with alooecia, which ha& been reported
